Milliken Completes Acquisition of Encapsys

US chemical producer Milliken has completed the acquisition of compatriot Encapsys from the Cypress Performance Group (CPG), a holding company formed by Sherman Capital Holdings in the merger of Encapsys with IPS Corporation.

Milliken’s management said the acquisition brings a unique combination of innovation, science and technology to the South Carolina-headquartered company. Coupled with Milliken’s ability to scale, the deal is expected to “propel efforts to deliver sustainable innovations.”

Appleton, Wisconsin-based Encapsys is regarded as a leading player in microencapsulation technologies, which put a uniform polymeric shell around a core material at the micron level to create capsules. These are leveraged by companies to achieve more sustainable products by advancing responsible consumption and efficient delivery of active materials, as Milliken explained.

As Encapsys is integrated into Milliken, the companies said daily operations will continue without interruption, including relationships with existing suppliers and customers.

Author: Dede Williams, Freelance Journalist

Milliken has completed the acquisition of compatriot Encapsys from the Cypress...
Milliken has completed the acquisition of compatriot Encapsys from the Cypress Performance Group. The Wisconsin firm is a leading player in microencapsulation technologies, which put a uniform polymeric shell around a core material at the micron level to create capsules. © AVAVA/Shutterstock

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read